Skip to main content

Advertisement

SpringerLink
Log in

Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson’s disease patients? A Systematic Review

  • Review
  • Published:
Neuropsychology Review Aims and scope Submit manuscript

Abstract

Many patients with Parkinson’s disease (PD) will develop cognitive impairment. Cross-sectional studies have shown that certain protein levels are altered in the cerebrospinal fluid (CSF) of PD patients with dementia and are thought to represent potential biomarkers of underlying pathogenesis. Recent studies suggest that CSF biomarker levels may be predictive of future risk of cognitive decline in non-demented PD patients. However, the strength of this evidence and difference between specific CSF biomarkers is not well delineated. We therefore performed a systematic review to assess if levels of specific CSF protein biomarkers are predictive of progression to cognitive impairment. Nine articles were identified that met inclusion criteria for the review. Findings from the review suggest a convergence of evidence that a low baseline Aβ42 in the CSF of non-demented PD patients predicts development of cognitive impairment over time. Conversely, there is limited evidence that CSF levels of tau, either total tau or phosphorylated tau, is a useful predictive biomarker. There are mixed results for other CSF biomarkers such as α-synuclein, Neurofilament light chain, and Heart fatty acid-binding protein. Overall the results of this review show that certain CSF biomarkers have better predictive ability to identify PD patients who are at risk for developing cognitive impairment. Given the interest in developing disease-modifying therapies, identifying this group will be important for clinical trials as initiation of therapy prior to the onset of cognitive decline is likely to be more efficacious.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1

Similar content being viewed by others

References

  • Aarsland, D., Zaccai, J., & Brayne, C. (2005). A systematic review of prevalence studies of dementia in Parkinson’s disease. Movement Disorders, 20(10), 1255–1263. doi:10.1002/mds.20527.

    Article  PubMed  Google Scholar 

  • Aarsland, D., Bronnick, K., Larsen, J. P., Tysnes, O. B., & Alves, G. (2009). Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology, 72(13), 1121–1126. doi:10.1212/01.wnl.0000338632.00552.cb.

    Article  CAS  PubMed  Google Scholar 

  • Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., et al. (2010). CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study. Journal of Neurology, Neurosurgery, and Psychiatry, 81(10), 1080–1086. doi:10.1136/jnnp.2009.199950.

    Article  PubMed  Google Scholar 

  • Alves, G., Lange, J., Blennow, K., Zetterberg, H., Andreasson, U., Forland, M. G., et al. (2014). CSF Abeta42 predicts early-onset dementia in Parkinson disease. Neurology, 82(20), 1784–1790. doi:10.1212/wnl.0000000000000425.

    Article  CAS  PubMed  Google Scholar 

  • Andersson, M., Wiig, E. H., Minthon, L., & Londos, E. (2007). A quick test for cognitive speed: a measure of cognitive speed in dementia with Lewy bodies. American Journal of Alzheimer’s Disease and Other Dementias, 22(4), 313–318.

    Article  PubMed  Google Scholar 

  • Backstrom, D. C., Eriksson Domellof, M., Linder, J., Olsson, B., Ohrfelt, A., Trupp, M., et al. (2015). Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurology. doi:10.1001/jamaneurol.2015.1449.

    PubMed  Google Scholar 

  • Benedict, R.H. (1997). Brief visuospatial memory test--revised: professional manual: PAR.

  • Benton, A. L., Hamsher, K., Varney, N. R., & Spreen, O. (1983). Judgment of line orientation. New York: Oxford University Press.

    Google Scholar 

  • Bjerke, M., Portelius, E., Minthon, L., Wallin, A., Anckarsäter, H., Anckarsäter, R., et al. (2010). Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. International Journal of Alzheimer’s disease, 2010.

  • Blennow, K., & Hampel, H. (2003). CSF markers for incipient Alzheimer’s disease. The Lancet Neurology, 2(10), 605–613.

    Article  CAS  PubMed  Google Scholar 

  • Blennow, K., Hampel, H., & Zetterberg, H. (2014). Biomarkers in amyloid-β immunotherapy trials in Alzheimer’s disease. Neuropsychopharmacology, 39(1), 189–201.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Bowie, C. R., & Harvey, P. D. (2006). Administration and interpretation of the trail making test. Nature Protocols, 1(5), 2277–2281.

    Article  CAS  PubMed  Google Scholar 

  • Broeders, M., de Bie, R. M., Velseboer, D. C., Speelman, J. D., Muslimovic, D., & Schmand, B. (2013a). Evolution of mild cognitive impairment in Parkinson disease. Neurology, 81(4), 346–352. doi:10.1212/WNL.0b013e31829c5c86.

    Article  CAS  PubMed  Google Scholar 

  • Broeders, M., Velseboer, D. C., de Bie, R., Speelman, J. D., Muslimovic, D., Post, B., et al. (2013b). Cognitive change in newly-diagnosed patients with Parkinson’s disease: a 5-year follow-up study. Journal of International Neuropsychological Society, 19(6), 695–708. doi:10.1017/s1355617713000295.

    Article  Google Scholar 

  • Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001). Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid β-peptide. Trends in Molecular Medicine, 7(12), 548–554.

    Article  CAS  PubMed  Google Scholar 

  • Caviness, J. N., Driver-Dunckley, E., Connor, D. J., Sabbagh, M. N., Hentz, J. G., Noble, B., et al. (2007). Defining mild cognitive impairment in Parkinson’s disease. Movement Disorders, 22(9), 1272–1277. doi:10.1002/mds.21453.

    Article  PubMed  Google Scholar 

  • Compta, Y., Marti, M. J., Ibarretxe-Bilbao, N., Junque, C., Valldeoriola, F., Munoz, E., et al. (2009). Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson’s disease. Movement Disorders, 24(15), 2203–2210. doi:10.1002/mds.22594.

    Article  PubMed  Google Scholar 

  • Compta, Y., Pereira, J. B., Rios, J., Ibarretxe-Bilbao, N., Junque, C., Bargallo, N., et al. (2013). Combined dementia-risk biomarkers in Parkinson’s disease: a prospective longitudinal study. Parkinsonism & Related Disorders, 19(8), 717–724. doi:10.1016/j.parkreldis.2013.03.009.

    Article  Google Scholar 

  • DeKosky, S. T., & Scheff, S. W. (1990). Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Annals of Neurology, 27(5), 457–464.

    Article  CAS  PubMed  Google Scholar 

  • Diniz, B. S., Pinto Junior, J. A., & Forlenza, O. V. (2008). Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. The World Journal of Biological Psychiatry, 9(3), 172–182. doi:10.1080/15622970701535502.

    Article  PubMed  Google Scholar 

  • Donnelly, K., Donnelly, J., Lichter, D., & Hershey, L. (1995). Longitudinal assessment of verbal and visual memory in Parkinson’s disease patients. Archives of Clinical Neuropsychology, 10(4), 322–323.

    Article  Google Scholar 

  • Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., et al. (2014). Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. New England Journal of Medicine, 370(4), 311–321.

    Article  CAS  PubMed  Google Scholar 

  • Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders, 22(12), 1689–1707. doi:10.1002/mds.21507. quiz 1837.

    Article  PubMed  Google Scholar 

  • Ewers, M., Walsh, C., Trojanowski, J. Q., Shaw, L. M., Petersen, R. C., Jack, C. R., Jr., et al. (2012). Prediction of conversion from mild cognitive impairment to Alzheimer’s disease dementia based upon biomarkers and neuropsychological test performance. Neurobiology of Aging, 33(7), 1203–1214. doi:10.1016/j.neurobiolaging.2010.10.019.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Fischer, P., Jungwirth, S., Zehetmayer, S., Weissgram, S., Hoenigschnabl, S., Gelpi, E., et al. (2007). Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology, 68(4), 288–291.

    Article  CAS  PubMed  Google Scholar 

  • Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189–198.

    Article  CAS  PubMed  Google Scholar 

  • Fournier, N., Geoffroy, M., & Deshusses, J. (1978). Purification and characterization of a long chain, fatty-acid-binding protein supplying the mitochondrial β-oxidative system in the heart. Biochimica et Biophysica Acta (BBA)-Protein Structure, 533(2), 457–464.

    Article  CAS  Google Scholar 

  • Gill, D. J., Freshman, A., Blender, J. A., & Ravina, B. (2008). The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson’s disease. Movement Disorders, 23(7), 1043–1046.

    Article  PubMed  Google Scholar 

  • Golden, C. (1978). Stroop colour and word test. AGE, 15, 90.

    Google Scholar 

  • Groth-Marnat, G. (2009). Handbook of psychological assessment: Wiley.

  • Hall, S., Ohrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., et al. (2012). Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Archives of Neurology, 69(11), 1445–1452. doi:10.1001/archneurol.2012.1654.

    Article  PubMed  Google Scholar 

  • Hall, S., Surova, Y., Ohrfelt, A., Zetterberg, H., Lindqvist, D., & Hansson, O. (2015). CSF biomarkers and clinical progression of Parkinson disease. Neurology, 84(1), 57–63. doi:10.1212/wnl.0000000000001098.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Halliday, G. M., Leverenz, J. B., Schneider, J. S., & Adler, C. H. (2014). The neurobiological basis of cognitive impairment in Parkinson’s disease. Movement Disorders, 29(5), 634–650. doi:10.1002/mds.25857.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Heaton, R. K. (1993). Wisconsin card sorting test: computer version 2. Odessa: Psychological Assessment Resources.

    Google Scholar 

  • Hely, M. A., Reid, W. G., Adena, M. A., Halliday, G. M., & Morris, J. G. (2008). The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Movement Disorders, 23(6), 837–844. doi:10.1002/mds.21956.

    Article  PubMed  Google Scholar 

  • Irwin, D. J., Lee, V. M., & Trojanowski, J. Q. (2013). Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nature Reviews Neuroscience, 14(9), 626–636. doi:10.1038/nrn3549.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Ivnik, R. J., Smith, G. E., Lucas, J. A., Tangalos, E. G., Kokmen, E., & Petersen, R. C. (1997). Free and cued selective reminding test: MOANS norms. Journal of Clinical and Experimental Neuropsychology, 19(5), 676–691.

    Article  CAS  PubMed  Google Scholar 

  • Johnson-Greene, D. (2004). Dementia rating scale-2 (DRS-2): by P.J. Jurica, C.L. Leitten, and S. Mattis: psychological Assessment Resources, 2001. Archives of Clinical Neuropsychology, 19(1), 145–147. doi:10.1016/j.acn.2003.07.003.

    Article  Google Scholar 

  • Kang, J. H., Irwin, D. J., Chen-Plotkin, A. S., Siderowf, A., Caspell, C., Coffey, C. S., et al. (2013). Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurology, 70(10), 1277–1287. doi:10.1001/jamaneurol.2013.3861.

    PubMed Central  PubMed  Google Scholar 

  • Kaplan, E. F., Goodglass, H., & Weintraub, S. (1983). The Boston naming test: experimental edition. Boston: Kaplan & Goodglass (2nd ed.). Philadelphia: Lea & Febinger.

  • Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010). Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurology, 9(12), 1200–1213. doi:10.1016/s1474-4422(10)70212-x.

    Article  PubMed  Google Scholar 

  • Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2013). Cognitive impairment in Parkinson’s disease: the dual syndrome hypothesis. Neurodegenerative Diseases, 11(2), 79–92. doi:10.1159/000341998.

    Article  PubMed  Google Scholar 

  • Leverenz, J. B., Watson, G. S., Shofer, J., Zabetian, C. P., Zhang, J., & Montine, T. J. (2011). Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson’s disease. Parkinsonism & Related Disorders, 17(1), 61–64. doi:10.1016/j.parkreldis.2010.10.003.

    Article  Google Scholar 

  • Lin, C.-H., & Wu, R.-M. (2015). Biomarkers of cognitive decline in Parkinson’s disease. Parkinsonism & Related Disorders, 21(5), 431–443.

    Article  Google Scholar 

  • Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I., et al. (2003). SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders. Movement disorders, 18(5), 467–486.

  • Litvan, I., Goldman, J. G., Troster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., et al. (2012). Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: movement disorder society task force guidelines. Movement Disorders, 27(3), 349–356. doi:10.1002/mds.24893.

    Article  PubMed Central  PubMed  Google Scholar 

  • Liu, C., Cholerton, B., Shi, M., Ginghina, C., Cain, K. C., Auinger, P., et al. (2015). CSF tau and tau/Abeta42 predict cognitive decline in Parkinson’s disease. Parkinsonism & Related Disorders, 21(3), 271–276. doi:10.1016/j.parkreldis.2014.12.027.

    Article  Google Scholar 

  • Llebaria, G., Pagonabarraga, J., Kulisevsky, J., Garcia-Sanchez, C., Pascual-Sedano, B., Gironell, A., et al. (2008). Cut-off score of the Mattis dementia rating scale for screening dementia in Parkinson’s disease. Movement Disorders, 23(11), 1546–1550. doi:10.1002/mds.22173.

    Article  PubMed  Google Scholar 

  • Lopes, M., Brucki, S. M. D., Giampaoli, V., & Mansur, L. L. (2009). Semantic verbal fluency test in dementia. Dementia & Neuropsychologia, 3, 315–320.

    Google Scholar 

  • Mattson, M. P. (2004). Pathways towards and away from Alzheimer’s disease. Nature, 430(7000), 631–639.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mitrushina, M., Boone, K.B., Razani, J., & D’Elia, L.F. (2005). Handbook of normative data for neuropsychological assessment: Oxford University Press.

  • Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology, 62(10), 1006–1012. doi:10.1016/j.jclinepi.2009.06.005.

    Article  PubMed  Google Scholar 

  • Mohs, R., Rosen, W., & Davis, K. (1983). The Alzheimer’s disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacology Bulletin, 19(3), 448.

    CAS  PubMed  Google Scholar 

  • Mollenhauer, B., Bibl, M., Wiltfang, J., Steinacker, P., Ciesielczyk, B., Neubert, K., et al. (2006). Total tau protein, phosphorylated tau (181p) protein, beta-amyloid(1–42), and beta-amyloid(1–40) in cerebrospinal fluid of patients with dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine, 44(2), 192–195. doi:10.1515/cclm.2006.035.

    Article  CAS  PubMed  Google Scholar 

  • Mollenhauer, B., Rochester, L., Chen-Plotkin, A., & Brooks, D. (2014). What can biomarkers tell us about cognition in Parkinson’s disease? Movement Disorders, 29(5), 622–633. doi:10.1002/mds.25846.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Mollenhauer, B., Parnetti, L., Rektorova, I., Kramberger, M. G., Pikkarainen, M., Schulz‐Schaeffer, W. J., et al. (2015). Biological confounders for the values of cerebrospinal fluid proteins in Parkinson’s disease and related disorders. Journal of Neurochemistry. doi:10.1111/jnc.13390.

    PubMed  Google Scholar 

  • Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina, C., et al. (2010). CSF Abeta(42) and tau in Parkinson’s disease with cognitive impairment. Movement Disorders, 25(15), 2682–2685. doi:10.1002/mds.23287.

    Article  PubMed Central  PubMed  Google Scholar 

  • Morris, J. C., Aisen, P. S., Bateman, R. J., Benzinger, T. L., Cairns, N. J., Fagan, A. M., et al. (2012). Developing an international network for Alzheimer’s research: the dominantly inherited Alzheimer network. Clinical Investigation, 2(10), 975–984.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Motter, N., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., et al. (1995). Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Annals of Neurology, 38(4), 643–648.

    Article  CAS  PubMed  Google Scholar 

  • Nombela, C., Rowe, J. B., Winder-Rhodes, S. E., Hampshire, A., Owen, A. M., Breen, D. P., et al. (2014). Genetic impact on cognition and brain function in newly diagnosed Parkinson’s disease: ICICLE-PD study. Brain, 137(Pt 10), 2743–2758. doi:10.1093/brain/awu201.

    Article  PubMed Central  PubMed  Google Scholar 

  • Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D’Amore, C., et al. (2008). Cerebrospinal fluid biomarkers in Parkinson’s disease with dementia and dementia with Lewy bodies. Biological Psychiatry, 64(10), 850–855. doi:10.1016/j.biopsych.2008.02.016.

    Article  CAS  PubMed  Google Scholar 

  • Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., et al. (2014). Differential role of CSF alpha-synuclein species, tau, and Abeta42 in Parkinson’s Disease. Frontiers in Aging Neuroscience, 6, 53. doi:10.3389/fnagi.2014.00053.

    Article  PubMed Central  PubMed  Google Scholar 

  • Rafii, M. S., & Aisen, P. S. (2015). Advances in Alzheimer’s disease drug development. BMC Medicine, 13, 62. doi:10.1186/s12916-015-0297-4.

    Article  PubMed Central  PubMed  Google Scholar 

  • Randall, K. D., & Kerns, K. A. (2011). Selective reminding test. In Encyclopedia of Clinical Neuropsychology (pp. 2235–2237): Springer.

  • Redding, G. M., & Gerjets, D. A. (1977). Stroop effect: interference and facilitation with verbal and manual responses. Perceptual and Motor Skills, 45(1), 11–17.

    Article  CAS  PubMed  Google Scholar 

  • Reid, W. G., Hely, M. A., Morris, J. G., Loy, C., & Halliday, G. M. (2011). Dementia in Parkinson’s disease: a 20-year neuropsychological study (Sydney Multicentre Study). Journal of Neurology, Neurosurgery, and Psychiatry, 82(9), 1033–1037. doi:10.1136/jnnp.2010.232678.

    Article  CAS  PubMed  Google Scholar 

  • Robbins, T. W., & Cools, R. (2014). Cognitive deficits in Parkinson’s disease: a cognitive neuroscience perspective. Movement Disorders, 29(5), 597–607. doi:10.1002/mds.25853.

    Article  PubMed  Google Scholar 

  • Scherling, C. S., Hall, T., Berisha, F., Klepac, K., Karydas, A., Coppola, G., et al. (2014). Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Annals of Neurology, 75(1), 116–126.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Schmidt, M. (1996). Rey auditory verbal learning test: a handbook. Los Angeles: Western Psychological Services.

    Google Scholar 

  • Sebaldt, R., Dalziel, W., Massoud, F., Tanguay, A., Ward, R., Thabane, L., et al. (2009). Detection of cognitive impairment and dementia using the animal fluency test: the DECIDE study. The Canadian Journal of Neurological Sciences, 36(05), 599–604.

    Article  PubMed  Google Scholar 

  • Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Annals of Neurology, 65(4), 403–413.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Siderowf, A., Xie, S. X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., et al. (2010). CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology, 75(12), 1055–1061. doi:10.1212/WNL.0b013e3181f39a78.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Smith, A. (2000). Symbol digit modalities test: SDMT: Testzentrale.

  • Sperling, R., Donohue, M., & Aisen, P. (2012). The A4 trial: anti-amyloid treatment of asymptomatic Alzheimer’s disease. Alzheimer’s & Dementia, 8(4), 425–P426.

    Article  Google Scholar 

  • Steering, D. (1989). DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Archives of Neurology, 46(10), 1052–1060.

    Article  Google Scholar 

  • Stewart, T., Liu, C., Ginghina, C., Cain, K. C., Auinger, P., Cholerton, B., et al. (2014). Cerebrospinal fluid alpha-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. The American Journal of Pathology, 184(4), 966–975. doi:10.1016/j.ajpath.2013.12.007.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Strozyk, D., Blennow, K., White, L., & Launer, L. (2003). CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology, 60(4), 652–656.

    Article  CAS  PubMed  Google Scholar 

  • Tachibana, H. (2013). Cognitive impairment in Parkinson’s disease. Seishin Shinkeigaku Zasshi, 115(11), 1142–1149.

    PubMed  Google Scholar 

  • Tariot, P. N., Ho, C., Langlois, C., Reiman, E. M., Lopera, F., Langbaum, J. B., et al. (2014). The Alzheimer’s prevention initiative. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 10(4), P247.

    Article  Google Scholar 

  • Terrelonge, M., Jr., Marder, K. S., Weintraub, D., & Alcalay, R. N. (2015). CSF beta-amyloid 1–42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. Journal of Molecular Neuroscience. doi:10.1007/s12031-015-0647-x.

    PubMed  Google Scholar 

  • Tombaugh, T. N., Kozak, J., & Rees, L. (1999). Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Archives of Clinical Neuropsychology, 14(2), 167–177.

    CAS  PubMed  Google Scholar 

  • Vanderploeg, R. D., Schinka, J. A., Jones, T., Small, B. J., Borenstein Graves, A., & Mortimer, J. A. (2000). Elderly norms for the hopkins verbal learning test-revised. The Clinical Neuropsychologist, 14(3), 318–324.

    Article  CAS  PubMed  Google Scholar 

  • Vranova, H. P., Henykova, E., Kaiserova, M., Mensikova, K., Vastik, M., Mares, J., et al. (2014). Tau protein, beta-amyloid(1)(−)(4)(2) and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. Journal of Neurological Sciences, 343(1–2), 120–124. doi:10.1016/j.jns.2014.05.052.

    Article  CAS  Google Scholar 

  • Wada-Isoe, K., Imamura, K., Kitamaya, M., Kowa, H., & Nakashima, K. (2008). Serum heart-fatty acid binding protein levels in patients with Lewy body disease. Journal of the Neurological Sciences, 266(1), 20–24.

    Article  CAS  PubMed  Google Scholar 

  • Warrington, E. K., & James, M. (1991). The visual object and space perception battery. Bury St Edmunds: Thames Valley Test Company.

    Google Scholar 

  • Williams-Gray, C. H., Evans, J. R., Goris, A., Foltynie, T., Ban, M., Robbins, T. W., et al. (2009). The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain, 132(Pt 11), 2958–2969. doi:10.1093/brain/awp245.

    Article  PubMed  Google Scholar 

  • Woods, S. P., Delis, D. C., Scott, J. C., Kramer, J. H., & Holdnack, J. A. (2006). The California verbal learning test–second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms. Archives of Clinical Neuropsychology, 21(5), 413–420.

    Article  PubMed  Google Scholar 

  • Yarnall, A. J., Breen, D. P., Duncan, G. W., Khoo, T. K., Coleman, S. Y., Firbank, M. J., et al. (2014). Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology, 82(4), 308–316. doi:10.1212/wnl.0000000000000066.

    Article  PubMed Central  PubMed  Google Scholar 

  • Zhang, J., Mattison, H. A., Liu, C., Ginghina, C., Auinger, P., McDermott, M. P., et al. (2013). Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathologica, 126(5), 671–682. doi:10.1007/s00401-013-1121-x.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was supported by grants from the NIH/NIA (AG047366), NIH/NIAAA (AA023165), NIH/NINDS (NS075097, NS091461, NS086085, and NS071675), and Michael J. Fox Foundation for Parkinson’s disease Research.

Author information

Authors and Affiliations

  1. Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, USA

    Katherine Leaver & Kathleen L. Poston

  2. Department of Neurosurgery, Stanford University, Stanford, CA, USA

    Kathleen L. Poston

Authors
  1. Katherine Leaver
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kathleen L. Poston
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen L. Poston.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leaver, K., Poston, K.L. Do CSF Biomarkers Predict Progression to Cognitive Impairment in Parkinson’s disease patients? A Systematic Review. Neuropsychol Rev 25, 411–423 (2015). https://doi.org/10.1007/s11065-015-9307-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11065-015-9307-8

Keywords

Search

Navigation